Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food ...

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts disc ...

Learn more about whether AbbVie Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to ...